Advertisement
YOU ARE HERE: LAT HomeCollectionsJohn I Gallin
IN THE NEWS

John I Gallin

FEATURED ARTICLES
NATIONAL
December 7, 2003 | David Willman, Times Staff Writer
"Subject No. 4" died at 1:44 a.m. on June 14, 1999, in the immense federal research clinic of the National Institutes of Health. The cause of death was clear: a complication from an experimental treatment for kidney inflammation using a drug made by a German company, Schering AG. Among the first to be notified was Dr. Stephen I. Katz, the senior NIH official whose institute conducted the study. Unbeknown to the participants, Katz also was a paid consultant to Schering AG.
ARTICLES BY DATE
NATIONAL
December 7, 2003 | David Willman, Times Staff Writer
"Subject No. 4" died at 1:44 a.m. on June 14, 1999, in the immense federal research clinic of the National Institutes of Health. The cause of death was clear: a complication from an experimental treatment for kidney inflammation using a drug made by a German company, Schering AG. Among the first to be notified was Dr. Stephen I. Katz, the senior NIH official whose institute conducted the study. Unbeknown to the participants, Katz also was a paid consultant to Schering AG.
Advertisement
NEWS
February 21, 1991 | MARLENE CIMONS, TIMES STAFF WRITER
A new drug has brought dramatic success in treating a rare, life-threatening immune-deficiency disorder and may be a valuable therapy for numerous other immune disorders, federal health officials said Wednesday. Researchers said that regular injections of recombinant gamma interferon can prevent serious infections and other complications of chronic granulomatous disease, or CGD, a hereditary condition of about 4,000 people worldwide.
NATIONAL
February 26, 2004 | David Willman, Times Staff Writer
The National Institutes of Health has not yet reported to Congress how much money its scientists have made consulting for drug companies despite a request made more than two months ago, a subcommittee chairman complained Wednesday. Rep. James C. Greenwood (R-Pa.), chairman of the House Oversight and Investigations Subcommittee, asked Health and Human Services Secretary Tommy G. Thompson for his assistance in forcing disclosure.
CALIFORNIA | LOCAL
February 21, 1991 | MARLENE CIMONS, TIMES STAFF WRITER
A new drug has shown dramatic success in treating a rare, life-threatening immune-deficiency disorder and may prove to be a valuable therapy for numerous other immune disorders, federal health officials said Wednesday.
NATIONAL
January 23, 2004 | David Willman and Jon Marino, Times Staff Writers
Top-level officials at the National Institutes of Health -- amid sharp criticism from congressional leaders -- have stopped accepting consulting fees and stock options from drug companies, the agency's leader told a Senate hearing on Thursday. "As of this moment, no director has any outside biotechnology or pharmaceutical relationship," said the leader of the NIH, Dr. Elias A. Zerhouni, referring to the directors of the agency's research institutes and centers. "Those have been stopped." Sen.
NATIONAL
January 17, 2004 | David Willman, Times Staff Writer
Three leading House Democrats on Friday asked the General Accounting Office to investigate consulting fees and stock options paid by drug companies to employees at the National Institutes of Health. Citing details from a Los Angeles Times article published last month, the House members called for an "investigation into potential conflicts of interest" at the federal government's center for medical research on humans.
NATIONAL
June 23, 2004 | David Willman, Times Staff Writer
The National Institutes of Health will drastically tighten policies that have allowed hundreds of consulting deals between drug companies and scientists at the nation's leading center for public health research, its director told a congressional panel Tuesday. Announcing a sweeping set of reforms, NIH Director Elias A. Zerhouni also said that he would demand public disclosure of any future industry payments to agency employees.
NATIONAL
May 7, 2004 | David Willman, Times Staff Writer
Senior officials at the National Institutes of Health should be barred from accepting income of any kind from drug companies, a panel examining conflict of interest at the agency recommended in its final report Thursday. The long-anticipated report of the Blue Ribbon Panel on Conflict of Interest Policies places the greatest pressure to date on NIH Director Elias A. Zerhouni to toughen agency policies. The report urged Zerhouni to adopt the recommendations "as quickly as possible."
NATIONAL
August 6, 2004 | David Willman, Times Staff Writer
The National Institutes of Health's recent proposals for cleaning up conflicts of interest do not reach far enough, the nation's chief ethics officer has concluded, putting new pressure on the agency to ban all drug industry payments to its scientists.
HEALTH
December 13, 1999 | BOB ROSENBLATT
Armed with information gained from the Internet and elsewhere, more patients than ever are referring themselves to clinical trials and tests of experimental drugs. That's a change from a time when most patients relied on their doctors to get into research studies. They are joining trials of experimental cancer drugs, new therapies to relieve arthritis pain and new treatments for depression.
Los Angeles Times Articles
|